Interactive Session - Use of Aromatase Inhibitors in Endometriosis and Ovulation Induction
Time:1:15 pm - 2:15 pm
Location:HCC313 - Hawaii Convention Center
Richard S. Legro, M.D. (Chair), Pennsylvania State University
Michael P. Diamond, M.D., Georgia Regents University
Serdar E. Bulun, M.D., Northwestern University
Needs Assessment and Description
This interactive session for reproductive-care physicians and allied health-care providers will examine the role of aromatase inhibitors in the treatment of common reproductive disorders, including polycystic ovary syndrome (PCOS), unexplained infertility, endometriosis, and uterine fibroids.
At the conclusion of this session, participants should be able to:
- Discuss the common side effects, adverse events, and any teratogenicity of aromatase inhibitors in the treatment of reproductive disorders.
- Identify the relative efficacy of aromatase inhibitors to treat PCOS vs. unexplained infertility.
Practice-based Learning and Improvement
A 31-year-old female presents with a history of unexplained infertility of 36 months’ duration, confirmed by evaluation of the male partner and tubal factor assessment. They have had no prior infertility treatment. The couple now presents for consultation to discuss treatment options and desires a safe and effective therapy to achieve a healthy singleton live-born baby. After participating in this session, in my practice I will recommend the following:
a. Expectant management for another 12 months
b. Clomiphene/intrauterine insemination (IUI) for 3-6 cycles
c. Letrozole/IUI for 3-6 cycles
d. Gonadotropin/IUI for 3-6 cycles
e. Immediate in vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI)
f. Not applicable to my area of practice